Since imatinib is known to inhibit PDGF-Rβ and decrease IFP in solid tumours, it has the potential to ‘normalise’ the tumour microenvironment and thereby improve delivery and efficacy of chemotherapeutic agents. The gene discussed is PDGFRB; the disease is neoplasm.